시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 중추신경계 바이오마커 시장 보고서(2025년)
Central Nervous System Biomarkers Global Market Report 2025
상품코드 : 1824349
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

중추신경계 바이오마커 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 10.0%를 나타내 89억 8,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 신경 질환의 유병률 증가, 맞춤형 의료에 대한 수요 증가, 노년 인구 증가, 조기 진단에 대한 관심 증가, 비침습 진단 도구에 대한 수요 증가로 인한 것으로 예측됩니다. 예측 기간의 주요 동향에는 신기술의 진보, 생명공학기업, 제약기업, 기타 이해관계자간의 전략적 제휴, 뇌척수액(csf) 및 혈액 기반 바이오마커에 대한 연구의 성장, AI 및 머신러닝 알고리즘의 활용 등이 있습니다.

향후 5년간의 성장률 10.0%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 상승은 스웨덴과 호주에서 조달하는 CSF 채취 시스템 및 타우 단백질 분석 비용을 밀어 올리고, 알츠하이머병의 진단 비용을 악화시키고, 신경퇴행성 질환 연구를 지연시킴으로써 미국의 신경학 연구에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

예상되는 신경질환 증가는 향후 중추신경계 바이오마커 시장 확대를 견인할 것으로 보입니다. 신경 질환은 신경 장애라고도 불리며 뇌, 척수 및 전신의 신경에 영향을 미치는 광범위한 증상을 포함합니다. 이러한 질병은 유전적 영향, 감염, 자가면역 반응, 퇴행 과정, 종양, 혈관 문제, 외상성 손상 등 다양한 요인들로부터 발생할 수 있습니다. 신경 질환의 영역에서 중추신경계(CNS) 바이오마커는 임상 진단, 질병 위험 및 예후 결정, 병기 평가, 치료 반응 모니터링에 중요한 역할을합니다. 이 바이오마커는 이러한 질병과 그 치료 가능성의 해명에 크게 기여합니다. 예를 들어, 2023년 4월 미국 정부 기관인 질병 관리 예방 센터는 알츠하이머병이 65세 이상의 미국인에게 추정 670만 명을 앓았다고 보고하고, 2060년까지 이 수가 3배인 1,400만명이 될 것으로 예측했습니다. 게다가 65세 이후는 5년마다 발병률이 배증한다고 합니다. 그 결과, 신경질환의 급증이 중추신경계 바이오마커 시장 성장을 가속하는 중요한 요인이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Central nervous system (CNS) biomarkers are specific substances or measurable indicators within the CNS that offer insights into normal functioning, disease processes, or responses to treatments. They play a crucial role in diagnosing or predicting neurological disorders, monitoring disease progression, and anticipating responses to drug therapy.

The primary categories of CNS biomarkers include safety biomarkers, efficacy biomarkers, validation biomarkers, and others. Safety biomarkers encompass measurable biological parameters or indicators employed to evaluate the safety of drugs, medical interventions, or environmental exposures. They find application in treating various diseases such as multiple sclerosis, Alzheimer's disease, traumatic brain injury, and more, contributing to drug discovery and development, personalized medicines, disease risk assessment, diagnostics, among other areas. Diverse end-users, such as diagnostic labs, clinics, hospitals, research centers, and others, utilize these biomarkers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The central nervous system biomarkers market research report is one of a series of new reports from The Business Research Company that provides central nervous system biomarkers market statistics, including central nervous system biomarkers industry global market size, regional shares, competitors with a central nervous system biomarkers market share, detailed central nervous system biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system biomarkers industry. This central nervous system biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The central nervous system biomarkers market size has grown strongly in recent years. It will grow from $5.58 billion in 2024 to $6.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rise in concerns regarding neurological disorders, high prevalence of central nervous system illnesses, growth in demand for enhanced diagnosis and treatment, improved healthcare infrastructure, rise in aging population.

The central nervous system biomarkers market size is expected to see strong growth in the next few years. It will grow to $8.98 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing prevalence of neurological disorders, growing demand for personalized medicine, rising geriatric population, increasing focus on early diagnosis, growing demand for non-invasive diagnostic tools. Major trends in the forecast period include new technological advancements, strategic collaborations between biotechnology companies, pharmaceutical companies, and other stakeholders, growth in research on cerebrospinal fluid (csf) and blood-based biomarkers, utilization of ai and machine learning algorithms.

The forecast of 10.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neurology research by driving up the cost of CSF collection systems and tau protein assays sourced from Sweden and Australia, exacerbating Alzheimer's diagnostic costs and delaying neurodegenerative disease research. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated increase in neurological illnesses is expected to drive the expansion of the central nervous system biomarker market in the future. Neurological illnesses, also referred to as neurological disorders, encompass a broad spectrum of conditions affecting the brain, spinal cord, and nerves throughout the body. These disorders can result from various factors, including genetic influences, infections, autoimmune responses, degenerative processes, tumors, vascular issues, and traumatic injuries. In the realm of neurological disorders, central nervous system (CNS) biomarkers play a crucial role in clinical diagnosis, determining illness risk or prognosis, assessing disease stage, and monitoring treatment response. They contribute significantly to comprehending these diseases and their treatability. For instance, in April 2023, the Centers for Disease Control and Prevention, a US government agency, reported that Alzheimer's disease affected an estimated 6.7 million Americans aged 65 and older, with projections indicating a tripling of this number to 14 million by 2060. Furthermore, the incidence of the disease is observed to double every five years after the age of 65. Consequently, the surge in neurological illnesses is a key factor propelling the growth of the central nervous system biomarker market.

The growing prevalence of obesity is expected to fuel the expansion of the central nervous system biomarker market in the coming years. Obesity, a medical condition marked by an excess of body fat, can adversely affect an individual's health. Central nervous system biomarkers are employed to study obesity, aiding in the understanding of the neurological mechanisms that control body weight and eating behavior, as well as in the development of effective anti-obesity treatments. For example, in March 2023, the World Heart Foundation, a Switzerland-based global cardiovascular organization, reported that approximately 2.3 billion adults and children worldwide are either obese or overweight. With current obesity trends, it is projected that the number of people affected by obesity will rise to 2.7 billion by 2025. Thus, the increasing prevalence of obesity is driving the growth of the central nervous system biomarker market.

A prominent trend gaining traction in the central nervous system biomarker market is the approval of innovative drugs. Leading companies in the market are dedicated to developing groundbreaking drugs and obtaining approvals to enhance their market standing. For example, in January 2022, Denovo Biopharma LLC, a clinical-stage biopharmaceutical company based in the US, disclosed the approval and authorization of its investigational new drug (IND) application for DB104 (liafensine) by the US Food and Drug Administration (FDA) for treating treatment-resistant depression (TRD). This marks the initiation of the first biomarker-guided global CNS clinical trial for TRD. The drug has the potential to identify patients more likely to respond to liafensine, facilitating more personalized treatment decisions. Liafensine, a novel compound, functions by elevating levels of dopamine and norepinephrine in the brain.

Major players in the central nervous system biomarker market are strategically focused on introducing advanced solutions, such as assay kits. An assay kit is a pre-packaged set of reagents and materials utilized for a specific scientific analysis. For instance, in June 2023, Sysmex Corporation, a research and development company based in Japan, launched an Automated Immunoassay System. This assay kit is designed to detect amyloid beta (AB) accumulation in the brain, a contributor to Alzheimer's disease, using a small blood sample. The kit measures the ratio of AB peptides in the blood through an automated immunoassay system. This facilitates clinicians in identifying AB accumulation in the brain with a minimal blood sample, enabling earlier diagnosis and treatment for patients.

In June 2022, Fujirebio Holdings Inc., a biotechnology company based in Japan, acquired ADx NeuroSciences for approximately $43 million (40 million euros). This acquisition aims to broaden Fujirebio Holdings' portfolio of central nervous system biomarkers, leverage ADx NeuroSciences' expertise and technology, and enhance its global presence in the central nervous system biomarker market. ADx NeuroSciences, headquartered in Belgium, is a biomarker-assay company specializing in the development and production of biomarkers for central nervous system (CNS) disorders.

Major companies operating in the central nervous system biomarkers market include F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics

North America was the largest region in the central nervous system biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the central nervous system biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The central nervous system biomarkers market consists of sales of diagnostic test kits, assay reagents, antibody drugs, and imaging agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Nervous System Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on central nervous system biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for central nervous system biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The central nervous system biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Central Nervous System Biomarkers Market Characteristics

3. Central Nervous System Biomarkers Market Trends And Strategies

4. Central Nervous System Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Central Nervous System Biomarkers Growth Analysis And Strategic Analysis Framework

6. Central Nervous System Biomarkers Market Segmentation

7. Central Nervous System Biomarkers Market Regional And Country Analysis

8. Asia-Pacific Central Nervous System Biomarkers Market

9. China Central Nervous System Biomarkers Market

10. India Central Nervous System Biomarkers Market

11. Japan Central Nervous System Biomarkers Market

12. Australia Central Nervous System Biomarkers Market

13. Indonesia Central Nervous System Biomarkers Market

14. South Korea Central Nervous System Biomarkers Market

15. Western Europe Central Nervous System Biomarkers Market

16. UK Central Nervous System Biomarkers Market

17. Germany Central Nervous System Biomarkers Market

18. France Central Nervous System Biomarkers Market

19. Italy Central Nervous System Biomarkers Market

20. Spain Central Nervous System Biomarkers Market

21. Eastern Europe Central Nervous System Biomarkers Market

22. Russia Central Nervous System Biomarkers Market

23. North America Central Nervous System Biomarkers Market

24. USA Central Nervous System Biomarkers Market

25. Canada Central Nervous System Biomarkers Market

26. South America Central Nervous System Biomarkers Market

27. Brazil Central Nervous System Biomarkers Market

28. Middle East Central Nervous System Biomarkers Market

29. Africa Central Nervous System Biomarkers Market

30. Central Nervous System Biomarkers Market Competitive Landscape And Company Profiles

31. Central Nervous System Biomarkers Market Other Major And Innovative Companies

32. Global Central Nervous System Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Central Nervous System Biomarkers Market

34. Recent Developments In The Central Nervous System Biomarkers Market

35. Central Nervous System Biomarkers Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기